Sign In
Buy INMB
$1.32
-0.1000 (-7.04%)
At Close: Jun 03, 2026
INmune Bio: XPro Trial Readout In Alzheimer's Disease Offers Big Opportunity
05:28pm, Thursday, 15'th May 2025
I rate INmune Bio, Inc. a speculative Strong Buy for high-risk investors, hinging on XPro's upcoming Phase II results in early Alzheimer's disease. XPro's unique mechanism targets neuroinflammation wi
INmune Bio, Inc. (INMB) Q1 2025 Earnings Call Transcript
03:57am, Saturday, 10'th May 2025
INmune Bio, Inc. (NASDAQ:INMB ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants David Moss - Chief Financial Officer Dr. RJ Tesi - Chief Executive Officer Dr. Mark Lowdell
INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update
04:10pm, Thursday, 08'th May 2025
BOCA RATON, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage biotechnology company targeting inflammation and immunology through the innate
INmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th
07:00am, Monday, 05'th May 2025
Boca Raton, Florida, May 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and n
INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness
08:00am, Monday, 14'th Apr 2025
Stevenage, UK, and Boca Raton, Florida, US, April 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) a clinical-stage biotechnology company targeting inflammation and immunology through the
INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript
08:15pm, Thursday, 27'th Mar 2025
INmune Bio, Inc. (NASDAQ:INMB ) Q4 2024 Results Conference Call March 27, 2025 4:30 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Mark Lowdell - Chief Scientific Officer
INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update
04:05pm, Thursday, 27'th Mar 2025
BOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that ha
Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West +
01:15pm, Friday, 21'st Mar 2025
The 'Undercovered' Dozen series highlights 12 lesser-covered stocks, offering fresh ideas and fostering discussion among investors. Mitsui & Co. is given a 'buy' recommendation, driven by Warren Buffe
INmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's Results
04:31pm, Tuesday, 18'th Mar 2025
INmune Bio's CORDstrom for RDEB shows promising results, supported by FDA designations, and could lead to a 9.8x stock revaluation. XPro for Alzheimer's has significant potential, with a $24.76 billio
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
07:00am, Wednesday, 12'th Feb 2025
BOCA RATON, Fla, Feb. 12, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, continues to advance its Natural Killer (NK
Boca Raton, Florida, Feb. 10, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”) , a clinical-stage inflammation and immunology company focused on developing treatments th
INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025
08:52am, Thursday, 02'nd Jan 2025
INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to outperform current treatments and attract big pharma interest. The Phase 2 trial fo
INmune Bio: XPro Cognitive Readout In Sight, But Mind The Financial Dangers
03:20pm, Monday, 30'th Dec 2024
INmune Bio, Inc.'s decline in 2024 is attributed to broader biotech sector issues, lack of significant clinical data, and inherent risks in Alzheimer's research. XPro, INMB's lead candidate, shows pot
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer's Trial with Vivo, a Novel genAI Clinical Trial Control Tower
09:00am, Wednesday, 04'th Dec 2024
Vivo Empowers Clinical Development Teams to Accelerate Decision-making and Analyses in Clinical Trials for Improved Outcomes HOUSTON and BOCA RATON, Fla., Dec. 04, 2024 (GLOBE NEWSWIRE) -- OmniScience
INmune Bio, Inc. (INMB) Q3 2024 Earnings Call Transcript
08:09pm, Thursday, 31'st Oct 2024
INmune Bio, Inc. (NASDAQ:INMB ) Q3 2024 Earnings Conference Call October 31, 2024 4:00 PM ET Company Participants David Moss - CFO Raymond Tesi - CEO & Co-Founder Christopher Barnum - Head of Neurosci
